



COHESIVE HEALTHCARE MANAGEMENT & CONSULTING

Mangum Regional Medical Center

TITLE		POLICY
Anaphylaxis/Adverse Drug Reaction Policy		DRM-053
MANUAL	EFFECTIVE DATE	REVIEW DATE
Drug Room	10-1-2020	10-1-2020
DEPARTMENT	REFERENCE	
Drug Room	Oklahoma Pharmacy Law Book	

SCOPE

This policy applies to all patients receiving care and treatment at MANGUM REGIONAL MEDICAL CENTER.

PURPOSE

To recognize the potential danger associated with any anaphylactic or adverse drug reaction to any drug given. To provide a consistent method of treating and reporting anaphylactic and adverse drug reaction.

DEFINITIONS

Adverse Drug Reaction: The American Society of Health-System Pharmacists (ASHP) defines an adverse drug reaction (ADR) as “Any unexpected, unintended, undesired, or excessive response to a drug that:

- a) Requires discontinuing the drug (therapeutic or diagnostic)
- b) Requires changing the drug therapy
- c) Requires modifying the dose (except for minor dosage adjustments)
- d) Necessitates admission to a hospital
- e) Prolongs stay in a health care facility
- f) Necessitates supportive treatment
- g) Significantly complicates diagnosis
- h) Negatively affects prognosis, or
- i) Results in temporary or permanent harm, disability, or death.

Anaphylaxis: A life-threatening allergic reaction that affects two or more parts of the body at once, including your skin, mouth, stomach, lungs or heart. Often it occurs as a series of reactions.

POLICY

All anaphylactic and/or adverse drug reactions will be reported to the Medical Provider, Pharmacy and Therapeutics (P&T), Quality, Medical Staff, and Governing Board committees.

PROCEDURE

1. In the initial nursing assessment, notes of allergy history of the patient and /or a strong family history associated with an allergy to any drug or food associated with drug reaction should be documented.
2. Food allergies associated with latex allergy such as kiwi, chestnut, bananas and avocados should be considered as potential warning signs.
3. Instruct the patient of the possibilities of allergic reaction which may manifest itself by symptoms such as generalized itching, tightness in the chest, a feeling of pressure, or difficulty breathing and immediately report these symptoms to healthcare personnel.
4. Establish a baseline data for vital signs of B/P, pulse, temp, respiration and pulse oximetry.
5. Keep a crash cart available.
6. Be alert for anaphylaxis or adverse drug reaction when administering any drug especially those with high potential for reaction such as PCN, Tetanus, allergy shots or any drug your patient has never taken before. Signs of anaphylaxis:
 - a) Urticaria
 - b) Edema
 - c) Hypotension
 - d) Disorientation
 - e) Cyanosis
 - f) Respiratory difficulty with or without wheezing
 - g) Hives
7. Discontinue drug at the first sign of possible symptoms.
8. Maintain an open IV.
9. Maintain an airway; apply oxygen as needed and notify Respiratory Therapy.
10. Place the patient in Trendelenburg position unless contraindicated.
11. Notify the ER provider or the medical provider on call.
12. If patient's condition is critical and the above measures fail, prepare to call for a Code Blue.
13. Document in nurses notes the reaction, condition and action taken.
14. Notify the House Supervisor and/or Charge Nurse of the anaphylactic or adverse drug reaction.
15. Complete an Incident Report and complete the information under Adverse Drug Reaction and forward to the Quality Manager (see Attachment A for details)
16. Any ADR that involves a newly FDA approved medication or involves an unusual or serious reaction not previously listed in a medication package insert, is to be submitted to the FDA through the MEDWATCH reporting program.

REFERENCES

<https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program>

ATTACHMENTS

Anaphylaxis/Adverse Drug Reaction Reporting Form

REVISIONS/UPDATES

Date	Brief Description of Revision/Change



Anaphylaxis/Adverse Drug Reaction Reporting Form

Medical Records Number: _____ Patient Name: _____ Provider _____
 Sex: Male _____ Female _____ Date/Time of: _____
 Observer's Name: _____ Date of Report: _____ Time of Report: _____

Event Detail: _____

Suspected Medication: _____ Dose: _____	
Route: _____	Frequency: _____ Rate of administration (if IV): _____
Date Med Ordered: _____	
Information on this reaction can be found on (date) ____/____/____ in: _____ Nurses Notes	
Reaction: _____	
Reaction on-set Time: _____	Was the Reaction Treated: _____ Yes _____ No
Date of Adverse Reaction: _____	
Describe Treatment: _____	

GENERAL CLASSIFICATION OF REACTION

- | | | |
|---|---|--|
| <input type="checkbox"/> Anaphylactic | <input type="checkbox"/> Elevated INR | <input type="checkbox"/> Musculoskeletal |
| <input type="checkbox"/> bleeding | <input type="checkbox"/> GI | <input type="checkbox"/> Neurologic |
| <input type="checkbox"/> Brady Cardia | <input type="checkbox"/> Hematologic | <input type="checkbox"/> Psychological |
| <input type="checkbox"/> Cardiac Arrest | <input type="checkbox"/> Hepatic | <input type="checkbox"/> Pulmonary |
| <input type="checkbox"/> Cardiovascular | <input type="checkbox"/> Hypotensive | <input type="checkbox"/> Renal |
| <input type="checkbox"/> Coma | <input type="checkbox"/> Infection | <input type="checkbox"/> Tachycardia |
| <input type="checkbox"/> Dermatologic | <input type="checkbox"/> Itching | <input type="checkbox"/> Urticaria |
| <input type="checkbox"/> Elevated Temp | <input type="checkbox"/> Metabolic (electrolytes) | <input type="checkbox"/> Vascular |
| | | <input type="checkbox"/> Vaccine |

Other: _____

OUTCOME:

MILD:

_____ required no intervention, no apparent harm to patient.

MODERATE:

_____ required treatment or intervention due to temporary harm.

_____ Increased monitoring.

_____ Prolonged hospitalization required.

SEVERITY:

_____ Death _____ Permanent Disability _____ Increased length of stay

Anaphylaxis/ADR outcome: _____ Reason for Admission _____ Preventable _____ Dose Related
 _____ to be reported to FDA

Person Completing this Form: _____